RxDoctor Payments DataLook up a doctor →

Jay Sandberg, DO

Internal Medicine · Troy, MINPI 1548293483

Payments from drug & device makers

$8,278,296in general payments, 2019–2025

Across 1,563 payments — averaging $5296.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3M
  • Modernatx, Inc.$1.4M
  • Sanofi US Services Inc.$1.1M
  • Janssen Research & Development, LLC$604K
  • Genentech, Inc.$438K
  • GSK$379K
  • plus $1.3M from 54 others
$138in research payments, 2019–2025

Across 1 payment — averaging $138.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$138

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer175$3,035,541
Modernatx, Inc.72$1,443,124
Sanofi US Services Inc.36$1,105,290
Janssen Research & Development, LLC36$603,987
Genentech, Inc.59$437,948
GSK56$379,485
AbbVie(2 entities)89$201,647
Noven Pharmaceuticals, Inc.20$159,438
AstraZeneca118$130,684
Cipla USA Inc.26$128,916
Otsuka Pharmaceutical Development & Commercialization, Inc.8$117,729
Sagent Pharmaceuticals18$99,076
Novartis27$85,548
Hoffmann-la Roche Limited5$84,780
GRT US Holding, Inc.19$84,018
Esperion Therapeutics, Inc.116$65,465
Bayer12$29,042
E.r. Squibb & Sons, L.L.C.6$17,744
Cosette Pharmaceuticals Inc.6$16,525
Chiesi USA, Inc.9$16,277
Kowa Research Institute, Inc.7$7,509
Novo Nordisk143$7,366
Amgen(2 entities)124$5,161
Regeneron1$5,000
Boehringer Ingelheim22$2,826
Takeda Pharmaceuticals U.S.A., Inc.13$1,498
Lilly USA, LLC74$1,131
Boehringer Ingelheim International GmbH7$672
Sanofi-aventis U.S. LLC33$555
Astellas Pharma US Inc22$534
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC31$501
Johnson & Johnson30$454
Merck17$362
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)13$350
Avanir Pharmaceuticals, Inc.13$233
Sumitomo Pharma America, Inc.11$208
Lundbeck LLC10$198
Abbott9$191
Exact Sciences7$148
Idorsia Pharmaceuticals US Inc5$106
Aimmune Therapeutics, Inc.6$105
Otsuka America Pharmaceutical, Inc.6$99
Amarin Pharma, Inc.6$85
Pacira Therapeutics, Inc.3$83
Biohaven Pharmaceuticals, Inc.4$72
Teva Pharmaceuticals USA, Inc.4$59
Nestle Healthcare Nutrition Inc.3$58
Eisai Inc.3$53
Axsome Therapeutics, Inc.2$48
Daiichi Sankyo Inc.3$44
Almatica Pharma LLC2$38
Corcept Therapeutics1$36
Dermira, Inc.2$34
Genentech USA, Inc.2$32
Biohaven Pharmaceutical Holding Company Ltd.2$28
Kyowa Kirin, Inc.1$26
Therapeuticsmd, Inc.2$25
Medicure Pharma Inc.1$23
Harmony Biosciences LLC1$21
Vertex1$18

How this compares

$8,278,296 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan →

Medicare billing

Part B allowed, 2024
$262,559
Medicare patients
366
Services billed
3,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Troy

See the full list for Michigan →

Where these figures come from

Is this you, or does something look wrong? →